ClinicalTrials.Veeva

Menu

Speech Treatment for Minimally Verbal Children With ASD and CAS (TxMVASD+CAS)

M

MGH Institute of Health Professions

Status

Enrolling

Conditions

Developmental Verbal Dyspraxia
Autism Spectrum Disorder

Treatments

Behavioral: CAS Treatment for Minimally Verbal Children with Autism

Study type

Interventional

Funder types

Other

Identifiers

NCT05066178
2021P002598

Details and patient eligibility

About

Comorbid Childhood Apraxia of Speech (CAS) may be one factor that limits speech development in some minimally verbal children with autism. CAS is a disorder affecting speech movement planning. This study tests whether CAS-specific treatment, appropriately modified for minimally verbal children with autism, improves their speech.

Full description

Although one in four children with autism remain minimally verbal past age five, not all the factors that limit spoken language in these minimally verbal children are known. One powerful contributor may be a motor speech disorder, Childhood Apraxia of Speech (CAS). CAS is an impairment in the ability to plan and sequence for speech, which makes speech inconsistent and imprecise. This project proposes to investigate whether CAS makes the speech of minimally verbal children with autism unintelligible, and then to test whether treating the CAS improves children's speech.

First, a cohort of 20 minimally verbal children with both autism and CAS is identified. The prediction is that the more severe the CAS, the more inconsistent and imprecise a child's speech, and therefore the lower their intelligibility will be. Then, a set of mono- and bisyllabic words is selected that contain the disordered movements that each child shows and use those in treatment.

Treatment will take the form of 15 one-hour sessions where speech practice is embedded in a naturalistic, play-based milieu that is centered on each child's own developmental level. It will involve principles of motor learning (intensive practice of a few words, sometimes all in a row and sometimes mixed up). Different types of cues (touch cues, simultaneous production, etc.) will also be employed to help children say their words correctly, fading back these supports as the child's speech improves. Both of these techniques have been shown to be effective for treating CAS.

Our outcome measures will include both (1) "by-ear" assessments of intelligibility and (2) acoustic and kinematic measurements of children's speech after 15 treatment sessions. The findings will inform clinical practice for minimally verbal children with autism and may lead to the development of novel interventions for this severely affected population.

Enrollment

20 estimated patients

Sex

All

Ages

5 to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Meets criteria for Autism Spectrum Disorder
  • Able to correctly repeat at least 2 syllables
  • Meets criteria for Childhood Apraxia of Speech
  • Lives in an environment where child is exposed to English at least 50% of the time

Exclusion criteria

  • Poorly controlled seizures
  • Factors such as blindness or deafness that contribute to minimally verbal status
  • Lives in an environment where English is not spoken at least 50% of the time
  • Child experiences behavioral challenges that preclude participation in the study

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

20 participants in 1 patient group

CAS Treatment for MV ASD
Experimental group
Description:
Participants will receive CAS treatment, modified for minimally verbal children with autism
Treatment:
Behavioral: CAS Treatment for Minimally Verbal Children with Autism

Trial contacts and locations

1

Loading...

Central trial contact

Karen V Chenausky, Ph.D.; Michael Moody

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems